LONDON, ON, Oct. 23 /CNW/ - The law firm Siskinds LLP launched a class
action today against C.B. Fleet Company, Inc. ("Fleet") regarding its oral
laxative, Fleet Phospho-soda.
Fleet Phospho-soda has been marketed in Canada since 1987. Since then,
the laxative has been commonly used as part of a bowel cleansing regimen in
preparing for surgery, x-ray or endoscopic examination.
Use of Fleet Phospho-soda has been linked to an increased risk of
developing renal damage and/or renal failure. A public advisory released in
December 2005 cited rare reports of patients who experienced a reduction in
kidney function, both temporarily and permanently, due to formation of calcium
deposits in their kidneys subsequent to their use of Fleet Phospho-soda for
The Statement of Claim alleges that Fleet failed to adequately warn
patients and physicians that Fleet Phospho-soda has been associated with an
increased risk of developing renal damage and/or renal failure. Michael
Eizenga, a partner with Siskinds LLP, says, "We believe that through this
lawsuit Fleet will be required to explain to Canadian consumers what it knew
about the risks associated with Fleet Phospho-soda and when it first became
aware of those risks. In this case, as with all of these types of cases, we
are concerned about whether Canadians were adequately warned of the risks
associated with using the product in question."
It is too early at this stage to quantify the claims of potential class
members, but it is anticipated that the amount is significant. Canadians who
have experienced adverse events from using Fleet Phospho-soda are encouraged
to visit www.classaction.ca or to call 1-800-461-6166. Quebec residents can
contact Claude Desmeules at (418) 694-2009.
For further information:
For further information: Michael Eizenga, at (519) 660-7820; or Matthew
Baer, at (519) 660-7782